<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01768247</url>
  </required_header>
  <id_info>
    <org_study_id>THINENDOM001</org_study_id>
    <nct_id>NCT01768247</nct_id>
  </id_info>
  <brief_title>HCG (Human Chorionic Gonadotropin) Priming for Thin Endometrium in IVF (in Vitro Fertilization)</brief_title>
  <official_title>HCG Priming for Thin Endometrium in IVF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Human Reproduction &amp; Genetics Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A thin endometrium is one of the most difficult problems encountered in assisted reproduction
      every day practice Regarding the proliferative phase, several ways of treatment have been
      undertaken to circumvent thin endometrium trying to increase thickness with questionable
      results.

      The objective of the current study will be whether a daily dose of 150 IU (international
      units) of human chorionic gonadotropin (HCG) for seven days concomitant with estrogen
      administration in estrogen replacement cycles can increase the endometrial thickness and
      improve pregnancy outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this pilot study subjects with repeatedly resistant thin endometrium, less than 6mm, will
      be recruited. The investigators sought to investigate the possible role of adding low dose
      HCG in the follicular phase, on the endometrial growth and development. The investigators
      constructed this hypothesis based on the fact that LH/HCG (luteinizing hormone/human
      chorionic gonadotropin) receptor is present in endometrium and therefore a positive
      interaction could be anticipated when HCG is administered in the proliferative phase of
      endometrial growth. Furthermore, in a previous study, where human menopausal gonadotropin
      (hMG) -well known that renders its luteinizing hormone (LH) capacity due to low dose HCG
      contain- was compared to recombinant-follicular stimulating hormone (rec-FSH) during ovarian
      stimulation, endometrium was more likely to be iso-echogenic and hypo-echogenic in the hMG
      group, also anticipating a possible positive role of HCG activity.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endometrial thickness</measure>
    <time_frame>14 days after estrogen treatment</time_frame>
    <description>measured by transvaginal ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcome</measure>
    <time_frame>5 weeks after embryotransfer</time_frame>
    <description>Clinical pregnancy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Endometrial Thickness</condition>
  <condition>Pregnancy Outcome</condition>
  <arm_group>
    <arm_group_label>HCG priming</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm after 7-9 days of estrogen replacement they will receive a 150 international units (IU) HCG every day for 7 days concomitantly with the estradiol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCG (human chorionic gonadotropin)</intervention_name>
    <description>150 international units (IU) of HCG for seven days subcutaneously concomitantly with estrogens in preparation endometrium cycles fro frozen embryos replacement</description>
    <arm_group_label>HCG priming</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (1) Less than 6mm endometrial thickness before, (2) at least two failed implantations
             before

        Exclusion Criteria:

          -  Abnormal uterine cavity in Hysteroscopy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Papanikolaou Evangelos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HRG clinical director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HRG Foundation</name>
      <address>
        <city>Thessaloniki</city>
        <state>Kalamaria</state>
        <zip>55133</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <link>
    <url>http://www.hrg.gr</url>
    <description>Facility web page</description>
  </link>
  <reference>
    <citation>Shufaro Y, Simon A, Laufer N, Fatum M. Thin unresponsive endometrium--a possible complication of surgical curettage compromising ART outcome. J Assist Reprod Genet. 2008 Aug;25(8):421-5. doi: 10.1007/s10815-008-9245-y. Epub 2008 Sep 17.</citation>
    <PMID>18797990</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2013</study_first_submitted>
  <study_first_submitted_qc>January 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2013</study_first_posted>
  <last_update_submitted>January 16, 2013</last_update_submitted>
  <last_update_submitted_qc>January 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>Papanikolaou Evangelos</investigator_full_name>
    <investigator_title>MD,PHD</investigator_title>
  </responsible_party>
  <keyword>endometrium</keyword>
  <keyword>thickness</keyword>
  <keyword>pregnancy</keyword>
  <keyword>HCG</keyword>
  <keyword>frozen cycles</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

